T he treatment of inflammatory bowel disease, with its relapsing and remitting nature, has benefitted greatly from the introduction of antibodies against tumor necrosis factor alpha (TNF-a). 1, 2 Adalimumab (ADA) is a recombinant human IgG1 monoclonal antibody against TNF-a and is an established treatment for both anti-TNF-naive and exposed patients. [3] [4] [5] [6] When offered the choice, a substantial proportion of the patients with Crohn's disease (CD) prefer subcutaneously administered anti-TNF, such as ADA, over intravenous anti-TNF. 7 The now widespread use of anti-TNF agents has shifted the bulk of inflammatory bowel disease health care costs from hospitalization and surgery to anti-TNF agents, with ADA making up 33.9% of all costs in patients with CD. 8 Thus, it seems that ADA is commonly prescribed to patients with CD, regardless of the sex of the patient.
However, it has previously been shown that the sex of the patient can have profound influences on drug metabolism and efficacy. For instance, in cardiovascular disease, the commonly used beta-blocker metoprolol has significantly higher drug concentrations in women than in men. 9 These differences are likely caused by sex-specific differences in body composition (e.g., proportion of body fat) and drug metabolism (e.g., cytochrome P450 [CYP] enzyme activity,). Although a biological agent such as ADA is not metabolized by CYP enzymes, sex-specific differences have been seen with biological drugs in other fields of medicine. Specifically, on a pharmacokinetic level several oncological-biological agents such as bevacizumab, cetuximab, and rituximab are cleared at different speeds between men and women. 10 Although the clinical implications of these pharmacokinetic differences are unclear, these differences again probably result from differences in body composition. 11 Of greater clinical relevance are observations in rheumatology, where female sex was found to be a significant negative predictor for longer ADA drug survival (i.e., the continued use of ADA). Particularly, lower drug survival was seen in women compared with men with arthritic psoriasis 12 and rheumatoid arthritis. 13 As such, the aim of this study was to investigate drug Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.ibdjournal.org).
survival of ADA and possible other sex differences in a cohort of 188 patients with CD.
MATERIALS AND METHODS

Design and Patients
A prospective clinical cohort was formed, consisting of 188 consecutive patients with CD who started ADA between March 2006 and February 2011 at the Erasmus University Medical Center, Rotterdam, the Netherlands. Patients with evidence of tuberculosis, chronic hepatitis B or C, or patients with immunodeficiency syndromes did not start ADA and thus were not part of the cohort.
Of all patients in the cohort, the following parameters were documented: sex, age at diagnosis, age at the start of ADA, Montreal disease classification, smoking behavior, body mass index, previous CD-related medical history (i.e., CD-related surgical history, previous CD-related drug therapies), and ADA start and stop date.
Where available, clinical disease activity through the Crohn's Disease Activity Index (CDAI) at the start of ADA therapy, C-reactive protein (CRP) at the start of therapy and ADA serum levels after 12 weeks of treatment were recorded. ADA serum levels were measured with enzyme-linked immunosorbent assay, as described previously. 14 Patient-reported side effects were also recorded.
All patients received a loading dose of 160 mg and 80 mg subcutaneously (sc) at weeks 0 and 2 respectively, followed by a maintenance dose of 40 mg sc every other week thereafter. ADA dose escalation occurred at the decision of the treating physician.
Patients were evaluated at the outpatient clinic at the start of ADA therapy and at least every 4 months thereafter. In cases where ADA therapy was ceased, further follow-up and treatment at the outpatient clinic occurred according to treatment guidelines. CDrelated therapies initiated during and after ADA therapy were also recorded. Data were recorded up to the last outpatient visit preceding August 01, 2015.
The primary outcome of interest was the ADA drug survival rate. Other outcomes of interest were sex-specific differences in drug survival and adverse events. Drug survival was evaluated by determining maintained clinical response, primary nonresponse, and secondary nonresponse. Primary nonresponse was defined as cessation of ADA therapy within 6 months because of lack of clinical improvement. Secondary nonresponse was defined as cessation of ADA therapy after at least 6 months of treatment (and thus, after an initial response) because of subsequent loss of response. Maintained response was defined as continued ADA therapy up to the end of follow-up. ADA cessation due to other reasons, such as side effects, was registered separately. Other outcomes of interest were the occurrence and outcome of dose escalation, reasons for stopping ADA, and adverse events to ADA.
Statistics
For all of the statistical analysis, the SPSS 21.0 software package was used. Descriptive statistics were used to summarize the data. Medians with range or means with SDs were calculated for continuous data as appropriate, and percentages were calculated for categorical data.
Variables were log-transformed as necessary and normality was assessed using Kolmogorov-Smirnov's test. Categorical data were compared using the x 2 test or Fisher's exact test. The Mann-Whitney test was used to compare continuous data. For all tests, 1-or 2-sided (as appropriate) P values ,0.05 were considered significant.
Ongoing ADA therapy was assessed using Kaplan-Meier analysis, with additional log-rank analyses to compare survival curves. Univariable Cox proportional hazard models were used to assess associations between ongoing ADA therapy and patient factors. The assumption of proportional hazards was assessed visually, using a log(2log[survival]) versus log of survival graph. In addition, a multivariable Cox proportional hazard model was constructed, using the predictors with a P value of ,0.20 in the univariable models, using stepwise backward elimination (probability of F to remove .0.10). To address potential sex-specific effects, interactions between sex and significantly different baseline characteristics were also assessed in this model. The number of predictors entered in the multivariable model was limited to the number of events divided by 10.
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RESULTS
Availability of Data
Of the 188 patients included in this study, body mass index values were missing in 4 patients, baseline CRP values in 24 patients, ADA serum levels in 58 patients, and baseline CDAI values in 63 patients.
Patient Characteristics
Between March 2006 and February 2011, 188 patients with CD were started on ADA treatment (Table 1 for patient details). Median follow-up was 6.0 years (range 0.3-9.2 yr). The total cohort consisted of 81 male and 107 female patients. At baseline, several sex differences were observed. First, more perianal involvement was seen in male patients (48.1% versus 33.6%, x 2 P ¼ 0.044), whereas higher median CDAI values were found in females (174 versus 154, Mann-Whitney U test P ¼ 0.036), with a trend for higher median CRP values in females as well (4.0 versus 3.0 mg/L, Mann-Whitney U test P ¼ 0.079). When examining previous drug exposure, a significantly larger proportion of female patients had received either no treatment or only 5-ASA before the start of ADA (13.1% versus 1.2%, Fisher's exact test P ¼ 0.003), whereas a trend was seen for more previous immunosuppressive use in males (45.7% versus 31.8%, x 2 P ¼ 0.052).
Reasons for starting ADA therapy (Table 2) included active luminal CD, maintaining a steroid induced remission, step-up therapy due to intolerance or inefficacy of immunosuppressive therapy, fistulas, extraintestinal manifestations, and other reasons. Steroid intolerance was significantly more often a starting reason for males than in females (9.9% versus 1.9%, Fisher's exact test P ¼ 0.021).
Clinical Outcomes to ADA Therapy Figure 1 displays the clinical outcomes to ADA therapy in this cohort, divided by male and female patients. In the first 6 months of treatment, 31 patients stopped ADA therapy, with a significantly greater proportion of female patients than male patients stopping ADA (21.5% versus 9.9%, x 2 P ¼ 0.034). Reasons for stopping were primary nonresponse in 13 patients, side effects in 15 patients, and other reasons in 3 patients (1· chemotherapy for testis carcinoma; 2· physician decision due to ongoing systemic infection). There were no statistically significant sex differences concerning the reason for stopping ADA in the first 6 months of treatment. Finally, 2 patients were lost to follow-up within the first 6 months of treatment.
The remaining 72 male and 83 female patients achieved an initial clinical response. During follow-up, 83 patients of the initial responders stopped ADA therapy. A trend for the proportional difference in female and male patients stopping ADA was seen (60.2% versus 45.8%, x 2 P ¼ 0.073). Reasons for stopping were secondary nonresponse in 39 patients, intolerance in 32 patients, and other reasons in 12 patients (5· patient decision, 4· malignancy, 2· pregnancy, 1· suspected malignancy). No statistically significant sex differences in the reason for stopping ADA were observed among the patients with an initial response. At the end of follow-up, 39 male and 33 female patients still had a clinical response, which translates into a significantly greater maintained clinical response rate in male than female patients (48.1% versus 30.8%,
Similarly, in Kaplan-Meier analysis, a difference was seen in male and female ADA continuation rates (Fig. 2 , log-rank P ¼ 0.006). In addition, in univariable and multivariable Cox proportional hazard models (Table 3) , male sex (beta ¼ 0.591, hazard ratio ¼ 1.807, P ¼ 0.020) predicted longer ADA treatment duration. A lower CDAI at start (beta ¼ 0.003, hazard ratio ¼ 1.003, P ¼ 0.003) was also predictive of longer ADA treatment duration. Previous anti-TNF exposure and steroid use at the start of ADA therapy were removed from the multivariable model during the backward stepwise elimination. Of note, no interactions were seen between CDAI and sex or between perianal involvement and sex, despite the baseline sex differences in these 2 variables.
ADA Dose Escalation
In total, 106 patients (56.4%) in the cohort had at least one episode of ADA dose escalation, including patients with escalation after ADA retreatment. In total, 140 ADA dose escalations occurred in these 106 patients. The proportion of female and male patients receiving dose escalation was not significantly different (57.0% versus 44.4%, x 2 P ¼ 0.842). The median ADA treatment duration before escalation was 13 months (range 1-95 mo), with a median escalation duration of 7 months (range 1-105 mo). Dose escalation led to recapture of response in 99 of 140 escalations (70.7%), with a significantly greater success percentage in male than in female patients (83.7% versus 60.7%, x 2 P ¼ 0.011). 
Side Effects
Most patients reported side effects to ADA. Only 50 patients (26.6%) did not report any side effects. In total, 254 adverse events were reported by 138 patients (see Table 1 , Supplemental Digital Content 1, http://links.lww.com/IBD/B406). Most commonly reported were injection site skin reactions such as erythema, bullae or hematomas (30), followed by respiratory tract infections (27) , arthralgia (24) , and generalized rash (23) . Hair loss (16) , fatigue (14) , skin infection (14) , nausea (13), dry skin (13), and headache (11) were also reported frequently.
Side effects were more often reported in females than in males (81.3% versus 64.2% respectively, x 2 P ¼ 0.008). In addition, the median amount of reported side effects was greater in females than in males (2 versus 1, Mann-Whitney U test P , 0.001). During the whole follow-up period, female patients stopped ADA more often due to side effects than male patients (35.4% versus 18.4%, x 2 P ¼ 0.017), whereas no significant differences were seen regarding stopping due to nonresponse or other reasons.
Regarding laboratory values, although mild liver enzyme abnormalities were seen in 123 patients, either these disturbances did not persist (69·), were present before ADA therapy (42·), or were clearly not caused by ADA (12·; e.g., due to thiopurine use, symptomatic cholelithiasis or postsurgery).
DISCUSSION
In this clinical CD cohort, we studied possible sex differences in the outcome to ADA treatment. At baseline, several differences already exist, chief among them a difference in previous therapies. In addition, we observed several sex differences concerning response, primarily a greater proportion of treatment in male patients than in female patients, of 48.1% and 30.8% respectively. Survival analysis in this cohort also underscores the effect of sex on ongoing ADA treatment, along with baseline disease activity. Furthermore, we find that female patients report more side effects and also cease ADA treatment more often due to side effects than male patients.
As this study was a prospective cohort, several baseline differences exist between male and female patients. Importantly, there is a difference in therapies preceding the start of ADA therapy. A significantly greater proportion of female patients were not treated with immunosuppressive drugs before the start of ADA. Although the reasons for not starting an immunosuppressive agent are unknown, possible explanations are a patient's fear of side effects and the preference of the treating physician for top-down anti-TNF treatment.
To our knowledge, our observed sex difference concerning response to ADA therapy has not been previously described in patients with CD, although it is in line with studies performed in rheumatology patients. One study in patients with psoriatic arthritis found that female sex was the strongest predictor of anti-TNF interruption in long-term anti-TNF treatment. 11 Similarly, a meta-analysis concerning patients with rheumatoid arthritis also reported that female sex predicts higher anti-TNF drug discontinuation rates. 12 In our study, the sex difference concerning response seems to be caused by differences in side effects. In our whole cohort, 25.0% of the whole cohort stopped ADA because of side effects, which is similar to previous studies. [15] [16] [17] However, unlike the aforementioned studies, we find that the distribution of patients stopping due to side effects is skewed toward female patients. However, a similar sex difference was seen in a study in 1009 patients with inflammatory bowel disease, of which 344 used anti-TNF (and 99 used ADA). In the whole anti-TNF subgroup, adverse reactions were seen more often in females than in males, and females stopped anti-TNF treatment more often due to adverse reactions than males, but no statistically significant difference was seen within the subgroup of 77 patients using ADA. 18 A possible explanation for the sex differences in side effects may lie in sex-specific physiological differences. On average, women have a smaller organ size and a higher proportion of body fat than men. In addition, in premenopausal women, the menstrual cycle results in fluctuations in the percentage of tissue water. These physiological differences result in different drug distribution volumes, and could thus lead to different responses to drug therapy. 19 In addition, modulation of CYP3A4 enzyme activity may also play a role. In general, women show higher CYP3A4 enzyme activity than men, 20 probably because of sex-related differences in sex hormone levels. However, CYP3A4 has been shown to be influenced by TNF-a, 21 thus the use of an anti-TNF agent such as ADA may influence CYP3A4 activity. Through this route, ADA may influence the metabolism of other commonly used drugs, possibly causing patients to experience side effects to these drugs, which in turn are attributed to ADA use. These effects may be further compounded by differences in perception of pain and adverse events in male and female patients. 22 Also, the clearance of ADA may differ between male and female patients. Mathematical modeling using data from patients with ulcerative colitis receiving infliximab showed a 33% lower drug clearance in females than in males. 23 Another modeling study among both patients with CD and ulcerative colitis showed approximately 50% lower drug clearance in females than in males. 24 However, it is unclear how this mathematical difference in infliximab clearance affects ADA serum levels, as previous reports did not find sex to significantly influence ADA serum levels. 25 Furthermore, the difference in disease activity and previous drug use at the start of ADA therapy suggests that female patients were slightly more ill at the start of therapy, possibly reflecting reluctance to start anti-TNF therapy in female patients. Also, the sex difference in previous drug exposure is also suggestive of some form of bias against the prescription of immunosuppressive agents in general to female patients. However, the possibility of female patients being more ill at the start of ADA therapy does not readily explain the observed sex difference in side effects occurring during the course of treatment.
Given the differences observed between men and women, it is conceivable that providing female patients with additional personalized information before the start of ADA therapy could reduce the observed sex difference in reported adverse reactions. Specifically, providing more information concerning the possible side effects may result in different patient expectations, which subsequently could reduce the high amount of drop-outs due to side effects, as observed in our study.
The efficacy of ADA in our whole cohort was similar to the efficacy reported in previous studies. Our 6.9% primary nonresponse rate is comparable with the 9% lack of response rate reported in the open-label arm of the CLASSIC-II trial. 4 Similarly, the 27% discontinuation rate (for reasons other than lack of response) is comparable with the findings from our cohort.
In this cohort, dose escalation to 40 mg every week occurred in 56.4% of patients, with some patients receiving multiple periods of dose escalation. This proportion is similar to the reported escalation rates in other studies, which vary from 13.2% to 63.4%. 26, 27 In our cohort, dose escalation was successful in 70.7% of attempts, similar to the reported success rate in other studies, which ranges from 36% to 86% in smaller studies, 26, 28 to 70% to 80% [29] [30] [31] as reported in larger studies.
Of note, we did not observe a sex difference in the need to dose escalate. This is similar to a study in 75 patients with CD requiring dose escalation, although this study did find that male patients required dose escalation earlier than female patients. 32 This real-life tertiary referral cohort has several limitations. Although our cohort is certainly not the largest ADA cohort to be reported on, our follow-up duration is relatively long. Also, the missing data at baseline may have influenced the results of the Cox analysis. Furthermore, the influence of CRP levels and CDAI scores during treatment could not be assessed, as these values were not regularly available during follow-up. In addition, because of the tertiary nature of our hospital, the patients enrolled in this cohort may not accurately reflect clinical practice in smaller regional hospitals. Finally, we were unable to gauge the efficacy of ADA through an objective endpoint such as mucosal healing.
In summary, in this clinical cohort of patients with CD treated with ADA, we reconfirm the overall efficacy of ADA for patients with CD. Moreover, we show several sex differences in response to ADA therapy. Chiefly, the success rate of ADA therapy is higher in males than in females, both for initial treatment, but also for dose escalation. The greater proportion of side effects in females seems to be the major cause to the difference in drug survival. This suggests that a personalized approach to female patients starting ADA could positively influence the incidence and severity of side effects and thus reduce the high drop-out rate seen in female patients.
